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Abstract The pathophysiology of exocrine dysfunction
observed in Sjo¨gren’s syndrome (SS) is not fully understood.
The purpose of this study was to investigate whether autoan-
tibodies against human AQP5 are present in the sera of SS
patients. Frozen sections of mouse submandibular salivary
glands, CHO cells over-expressing a human AQP5–GFP
fusion protein or GFP, and MDCK cells over-expressing
AQP5 were used in the indirect immunofluorescence assay to
detect anti-AQP5 autoantibodies in the sera from patients with
primary SS. The lysates of HEK-293 cells over-expressing the
AQP5–GFP fusion protein or GFP were used for immuno-
precipitation. Serum IgG from the SS patients but not from the
control subjects stained acinar cells in the mouse salivary
glands, the signals of which colocalized with those of AQP5-
specific antibodies. Serum IgG from the SS patients also
selectively stained AQP5–GFP expressed in CHO cells.
However, both the control and SS sera immunoprecipitated
the AQP5–GFP, suggesting that autoantibodies against AQP5
were also present in the control sera. The screening of 53
control and 112 SS samples by indirect immunofluorescence
assay using the AQP5-expressing MDCK cells revealed the
presence of significantly higher levels of anti-AQP5 IgG in the
SS samples than in the control samples with sensitivity of 0.73
and a specificity of 0.68. Furthermore, the presence of anti-
AQP5 autoantibodies was associated with low resting salivary
flow in SS patients. In conclusion, anti-AQP5 autoantibodies
were detected in the sera from SS patients, which could be a
novel biomarker of SS and provide new insight into the
pathogenesis of SS.
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Introduction
Sjo¨gren’s syndrome (SS) is an autoimmune disorder that
primarily targets the salivary and lacrimal glands, leading to
dryness of the mouth and eyes [1]. In addition to glandular
dysfunction, SS patients often present with extra-glandular
manifestation, such as tubulointerstitial nephritis, primary
biliary cirrhosis, autoimmune cholangitis, autoimmune
hepatitis, interstitial lung disease, and the development of
lymphocytic malignancies [2–7]. The disease may occur as
the primary condition or as a secondary phenomenon in
association with other autoimmune diseases, including
rheumatoid arthritis, systemic lupus erythematosus, and
progressive systemic scleroderma [8]. SS is a multifactorial
disease: environmental factors trigger immune responses
that damage the salivary and lacrimal gland cells in indi-
viduals with a genetic predisposition to the disease [1].
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Glandular dysfunction had been understood as a result
of apoptotic destruction of acinar cells by infiltrated cyto-
toxic T cells because the salivary and lacrimal glands of SS
patients present abundant lymphocytic infiltration and
atrophy [1]. However, the results of more recent studies
suggest that glandular dysfunction precedes glandular
atrophy. For example, many SS patients with no glandular
function retain substantial amounts of intact acinar tissues
in their salivary glands. Furthermore, those acinar tissues
regain functionality in vitro [9]. The paradigm for glan-
dular hypofunction in SS has thus been shifted toward
interference with the secretion process. The control of
salivary and lacrimal secretion is governed by muscarinic
nerves through the type 3 muscarinic acetylcholine recep-
tor (M3R). Although anti-M3R autoantibody-mediated
inhibition of M3R function partially explains the dys-
function of the acinar cells [10], the pathophysiology of
exocrine dysfunction observed in SS is not fully
understood.
Aquaporin-5 (AQP5), a major water channel protein
expressed in the lacrimal and salivary glands, has a critical
role in tear and saliva secretion [11]. AQP5-deficient mice
secrete hypertonic saliva with a substantially reduced vol-
ume [12], which is attributed to a decrease in the water
permeability of salivary acini [13]. Anti-AQP4 autoanti-
bodies are detected in patients with neuromyelitis optica,
and the presence of anti-AQP4 IgG in the sera is used as a
gold standard for the differential diagnosis of neuromyelitis
optica from multiple sclerosis [14]. We hypothesized that
SS patients may have autoantibodies against AQP5. The
purpose of this study was to investigate whether autoanti-




This study was done in compliance with the Helsinki
Declaration after approvals from the Institutional Review
Board of Seoul National University Hospital (IRB Number:
0912-011-302), the Institutional Review Board of Seoul
National University School of Dentistry (IRB Number:
S-D20140022), and the Institutional Review Board of
Seoul St. Mary’s Hospital (IRB Number:
KC13ONMI0646). The study also conformed to the
STROBE guidelines. For this pilot case–control study,
serum samples were obtained from two groups of patients:
(1) 10 primary SS patients enrolled at the Rheumatology
Clinic, Seoul National University Hospital, who were
diagnosed according to the 2002 American-European
Consensus group (AECG) classification criteria for primary
Sjo¨gren’s syndrome [15] and (2) 102 primary SS patients
enrolled at the Korean Initiative of primary Sjo¨gren’s
Syndrome (KISS) who fulfilled the 2002 American-Euro-
pean Consensus group (AECG) classification criteria and/
or the 2012 American College of Rheumatology (ACR)
criteria [16]. The samples included in the pooled sera were
chosen based on the availability. All samples were obtained
before starting treatment. In addition, resting and stimu-
lated whole salivary flow rates were measured by spiting
and masticatory stimuli using wax gum (GC America Inc,
St. Alsip, IL, USA), respectively, according to the method
previously described [17]. All patients were females with
ages ranging from 21 to 80 years (mean age
52.5 ± 10.7 years). Control sera were obtained from 53
healthy female controls who did not show any signs of SS
symptoms (mean age 37.1 ± 7.4 years). Subjects with
systemic disease other than hypertension were excluded.
Written informed consent was obtained from all the
subjects.
Cell culture
All cell lines were obtained from Korean Cell Line Bank
(Seoul, Korea). Chinese hamster ovary (CHO) cells were
cultured in F-12 medium containing 10 % FBS and 1 %
penicillin/streptomycin, while human embryonic kidney
(HEK)-293 cells and Madin-Darby canine kidney (MDCK)
cells were maintained in DMEM medium with 10 % FBS
and 1 % penicillin/streptomycin.
AQP5-encoding constructs and transfection of cells
The AQP5 cDNA was cloned into a pEGFP-N1 vector
(Clontech, Mountain View, CA, USA) using XhoI and
BamHI sites and into a pcDNA3.1 vector (Invitrogen,
Carlsbad, CA, USA) using BamHI and XhoI restriction
sites. The cloned plasmids were transfected into cells with
the calcium phosphate precipitation method [18].
Indirect immunofluorescence assay (IIFA)
For IIFA, all tissues and cells were fixed with 4 %
paraformaldehyde in PBS pH 7.4, subjected to antigen
retrieval by incubation in sodium citrate buffer pH 6 at
105 C for 20 min, and then permeabilized with 0.3 %
Triton X-100 before blocking and incubation with primary
antibodies, which gave the best result by staining with the
commercial anti-AQP5 antibodies.
The use of animal tissues followed a protocol approved
by the Seoul National University Animal Care and Use
Committee. After stimulating 12-week-old C57BL/6 mice
(Orient Bio Inc., Seongnam, Gyeonggi, Korea) with 5 lg/g
body weight of pilocarpine (Sigma-Aldrich Korea, Seoul,
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Korea), the submandibular glands were removed and fixed
with 4 % paraformaldehyde in PBS pH 7.4 overnight. The
fixed tissues were immersed in 30 % sucrose–PBS pH 7.4
and embedded in the OCT compound. Cryostat sections
were mounted on saline-coated glass slides (Muto pure
chemicals, Tokyo, Japan) and air-dried. After antigen
retrieval and permeabilization, the sections were blocked
with 5 % BSA in PBS and were then incubated with goat
anti-AQP5 antibodies (Santa Cruz, Paso Robles, CA, USA)
and either the pooled SS or pooled control sera (1:200
dilution) overnight, followed by Alexa Fluor 488-conju-
gated donkey anti-goat IgG (Invitrogen) and CFTM
594-conjugated rabbit anti-human IgG antibodies (Sigma-
Aldrich).
CHO cells cultured on collagen-coated glass slides were
transfected with either pEGFP-N1-AQP5 or pEGFP-N1.
MDCK cells were transfected with pcDNA3.1-AQP5. The
transfected CHO cells were incubated with rabbit anti-GFP
antibodies (Sant Cruz) and either the pooled control or the
pooled SS sera (1:200 dilution), followed by Alexa Fluor
488-conjugated goat anti-rabbit and Alexa Fluor 555-con-
jugated goat anti-human IgG (Invitrogen). The transfected
MDCK cells were incubated with goat anti-AQP5 and
various dilutions of either the control or SS sera, followed
by Alexa Fluor 488-conjugated donkey anti-goat IgG and
CFTM 594-conjugated rabbit anti-human IgG. To detect
human IgA, Alexa flour 594-conjugated rabbit anti-human
IgA antibodies (Jackson ImmunoResearch, West Grove,
PA, USA) were used. All images were taken with a con-
focal microscope LSM 700 (Carl Zeiss, Jena, Germany). In
the case of the stained MDCK–AQP5 cells, three areas of
AQP5-expressing cells were randomly selected and
sequentially imaged for the presence of anti-AQP5 IgG/
IgA. Because many SS samples had stained nuclei as well
as AQP5, the relative intensities of the anti-AQP5 signals
were determined by decreasing the brightness of the red
signal until the signals of the anti-AQP5 IgG/IgA disap-
peared. The mean of the D brightness obtained in three
images was used to express the level of anti-AQP5 IgG/IgA
for each sample.
Immunoprecipitation and western blot
HEK-293 cells were transfected with pAQP5-EGFP or
pEGFP-N1. Forty-eight hours after transfection, cells were
lysed with lysis buffer (40 mM octyl-b-D-1-thioglucopy-
ranoside, 50 mM Tris–HCl, and 150 mM NaCl, pH 7.4).
Proteins (250 lg of cell lysates) were incubated with 1 lg
anti-AQP5 antibodies, pooled control sera, or pooled SS
sera overnight, followed by precipitation with protein A
agarose beads (Pierce Biotechnology, Rockford, IL, USA).
After washing, the beads were resuspended in Laemmli
sample buffer containing b-mercaptoethanol and incubated
at 70 C for 15 min. The proteins were separated on a
12 % SDS-PAGE gel, transferred to PVDF membrane
(Millipore, Billerica, MA, USA), and immunoblotted with
goat anti-AQP5 or rabbit anti-GFP antibodies.
Statistics
With the levels of anti-AQP5 IgG/IgA detected in the SS
and control groups, a receiver operating characteristic
(ROC) analysis by a nonparametric method and the Mann–
Whitney U test were performed. Associations between
measures of salivary rate and the presence of autoanti-
bodies were examined using one-way analysis of variance.
Because some groups did not pass the normality test, the
difference was also analyzed by Mann–Whitney U test. All
statistics were performed using SPSS (SPSS Inc., Chicago,
USA).
Results
Serum IgG from SS patients stain AQP5 in mouse
salivary glands
To investigate the presence of autoantibodies against
AQP5 in the sera of SS patients, sections of mouse salivary
glands were dual-stained with the pooled sera of patients
(n = 4) and AQP5-specific goat IgG that targets the
cytoplasmic tail of murine, rat, and human AQP5. The
amino acid sequence of AQP5 is highly conserved between
humans and mice with 91 % identities and 96 % homol-
ogy. AQP5 expression was observed at the apical site of the
serous acinar cells in the highest levels and also at the
basolateral site of both the mucous and serous acinar cells
but not in the ductal cells, as previously reported [19].
While the pooled sera of control subjects (n = 4) barely
stained the mouse salivary glands, the SS sera strongly
stained the nuclei and plasma membranes of the acinar
cells (Fig. 1a). The signals of SS IgG showed a high degree
of colocalization with those of AQP5-specific goat IgG,
which was confirmed with Mander’s overlap coefficient
(Fig. 1b).
Serum IgG from SS patients selectively stain AQP5–
GFP-transfected cells
Because SS patients may have autoantibodies against other
proteins expressed in the salivary gland, the specificity of
the autoantibodies was further investigated with CHO cells
transfected with a transgene encoding a human AQP5–GFP
fusion protein or GFP alone. While the GFP was dispersed
850 Immunol Res (2016) 64:848–856
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throughout the cytoplasm and nuclei, AQP5–GFP was
localized mostly to the plasma membranes and vesicular
organelles. The anti-AQP5 goat IgG stained the CHO cells
expressing AQP5–GFP but not those expressing GFP
alone. The pooled SS sera stained the nuclei of the CHO
cells regardless of the type of transgene but also specifi-
cally stained the cells expressing AQP5–GFP. The pooled
control sera did not stain either GFP- or AQP5–GFP-ex-
pressing cells (Fig. 2a). The signals of both anti-AQP5 goat
IgG and SS IgG overlapped with the signal of GFP local-
ized to the plasma membrane and intracellular vesicles in
the AQP5–GFP-expressing cells, which was confirmed
with Mander’s overlap coefficient (Fig. 2b).
Both the control and SS sera immunoprecipitate
AQP5–GFP
The selective staining of AQP5–GFP but not of GFP by the
SS sera suggests that AQP5 acts as an autoantigen in the SS
patients. However, colocalization, i.e., co-occurrence of
two fluorophores in the same pixel, does not necessarily
mean that the two signals target the same molecule.
Therefore, the specific binding of SS IgG to AQP5 was
further studied by immunoprecipitation. HEK-293 cells
were transfected with either pEGFP-N1 or pAQP5-GFP
which express the 27 KD GFP and 55 KD AQP5–GFP
proteins, respectively (Fig. 3a). The anti-AQP5 IgG
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Fig. 1 Serum IgG from SS patients co-localizes with AQP5 in the
mouse salivary glands. a Sections of the mouse submandibular gland
were stained with goat anti-AQP5 antibodies and either the pooled
control or pooled SS sera followed by Alexa Fluor 488-conjugated anti-
goat IgG and CFTM 594-conjugated anti-human IgG. The areas of
mucous and serous acini were imaged with confocal microscopy.
D duct; arrows nuclei. b The colocalization of green and red signals in
























































Fig. 2 Serum IgG from SS patients selectively stains AQP5–GFP-
transfected cells. a CHO cells were transfected with either pEGFP-N1
or pAQP5-EGFP. The transfected cells were stained with goat anti-
AQP5 antibodies, control sera, or SS sera (red) together with anti-GFP
antibodies (green). b The colocalization of green and red signals in 18
images were calculated with Mander’s coefficient (Color figure online)
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precipitated the AQP5–GFP, which was not precipitated
from the lysates of the HEK-293 cells expressing GFP
alone. Both the control and SS sera precipitated the AQP5–
GFP, suggesting the presence of autoantibodies against
AQP5 not only in the SS sera but also in the control sera
(Fig. 3b left panel). When decreased amounts of sera were
used, however, only the SS sera precipitated AQP5–GFP
(Fig. 3b right panel). In an additional blinded experiment
using several control and SS sera, all samples immuno-
precipitated AQP5–GFP (data not shown).
Higher levels of anti-AQP5 IgG and IgA were
detected in the SS sera by IIFA
Currently, the standard method to detect anti-AQP4
autoantibodies for the diagnosis of neuromyelitis optica is
with IIFA [20]. Therefore, a similar cell-based IIFA was
developed by over-expressing AQP5 in MDCK cells which
have been widely used in studies on AQP5 function [21,
22]. The staining protocol was first optimized with the
pooled sera. Both the SS and control sera contained anti-
AQP5 IgG; however, a clear difference in their titers was
observed (Fig. 4a). The 1:200 dilution was chosen to
screen 53 control and 112 SS samples for anti-AQP5 IgG.
The anti-AQP5 IgG was detected in 43 control and 103 SS
samples with a significant difference in their intensities
(p\ 0.0001). When the cutoff value was set as the
mean ? 2 SD of the control values, 35 (31.3 %) SS sam-
ples were positive for the anti-AQP5 IgG (Fig. 4b left
panel, cutoff 1). When the cutoff value at which the
accuracy was the highest was chosen from the ROC curve
(Fig. 4b right panel), 17 (32.1 %) control and 82 (73.2 %)
SS samples were positive for the anti-AQP5 IgG, resulting
in a sensitivity of 0.73 and a specificity of 0.68 (Fig. 4b left
panel, cutoff 2). We also screened the samples for the
presence of anti-AQP5 IgA with a 1:20 dilution (Fig. 4c).
The anti-AQP5 IgA was detected in only one (1.9 %)
control and 15 (13.4 %) SS samples, where the cutoff was
set as the mean ? 2 SD of the control values (Fig. 4d). All
the anti-AQP5 IgA-positive samples also contained anti-
AQP5 IgG, although the levels of anti-AQP5 IgG did not
reach the cutoff 2 in four SS samples. Therefore, total 86
(76.8 %) SS samples were positive for either anti-AQP5
IgG or IgA.
The presence of anti-AQP5 autoantibodies
was associated with low salivary flow rate
Associations between the presence of anti-AQP5 IgG (by
cutoff 2) or IgA autoantibodies and salivary flow rates were
examined in patients for whom the salivary flow rates were
recorded at the time of sampling. The presence of anti-
AQP5 IgG was associated with low resting salivary flow
but not with stimulated salivary flow. The patients with
anti-AQP5 IgA presented lower levels of both resting and
stimulated salivary flow than those without the autoanti-
bodies. However, significance was achieved for only rest-
ing salivary flow (Table 1 and Supplementary Table 1).
Importantly, the presence of either anti-Ro or anti-La
antibodies was not associated with the levels of salivary





























































a b 1 μl 0.75 μl
25 kD
55 kD
Fig. 3 Both the control and SS sera immunoprecipitate AQP5–GFP.
HEK-293 cells were transfected with either pEGFP-N1 or pAQP5-
EGFP. a Lysates of non-transfected and transfected HEK-293 cells
were separated by SDS-PAGE and immunoblotted with anti-AQP5 or
anti-GFP antibodies. b Lysates of HEK-293 cells transfected with
either pEGFP-N1 or pAQP5-EGFP were incubated with anti-AQP5
antibodies, control sera, or SS sera. The immune complexes
precipitated with protein A agarose beads were immunoblotted with
either anti-AQP5 or anti-GFP antibodies
























































Fig. 4 Higher levels of anti-AQP5 IgG and IgA were detected in the
SS sera by IIFA. a MDCK cells over-expressing AQP5 were stained
with anti-AQP5 antibodies and various dilutions of either the control
or SS sera, followed by Alexa Fluor 488-conjugated anti-goat IgG
(green) and CFTM 594-conjugated anti-human IgG (red). b The
intensities of the red signals for anti-AQP5 IgG were expressed by the
magnitude of brightness that was reduced until the staining of AQP5
disappeared. A ROC curve for the levels of anti-AQP5 IgG is shown.
The arrow indicates the value used for cutoff 2 in the left panel.
c MDCK cells over-expressing AQP5 were stained with anti-AQP5
antibodies and either the control or SS sera (1:20 dilution), followed
by Alexa Fluor 488-conjugated anti-goat IgG (green) and Alexa Fluor
555-conjugated anti-human IgA (red). d The intensities of the red
signals for anti-AQP5 IgA were expressed by the magnitude of
brightness that was reduced until the staining of AQP5 disappeared
(Color figure online)
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Discussion
The results of this study showed that autoantibodies against
AQP5 are present in the sera of SS patients. Furthermore,
patients with anti-AQP5 autoantibodies presented signifi-
cantly lower resting salivary flow than those without the
anti-AQP5 antibodies. This is the first report on the asso-
ciation between anti-AQP5 autoantibodies and SS. Like
other AQPs, AQP5 consists of six transmembrane alpha
helixes connected by five loops, and the protein forms a
water channel as narrow as 1–4 A˚ through the plasma
membrane [23]. If antibodies bind to the extracellular loops
of AQP5, the antibodies may block the passage of water
molecules through the channel. AQP5 is mainly localized
to the apical membrane of acinar cells and intercalated
ducts. AQP5 has also been found at the basolateral mem-
brane of acinar cells in the mouse salivary glands [19];
however, the basolateral localization of AQP5 in normal
human salivary glands has not been reported yet. Although
dyslocalization of AQP5 from the apical to the basolateral
sites of acinar cells in SS patients has been reported by two
groups, the other two groups reported no difference in the
subcellular localization of AQP5 between the normal and
SS salivary glands [24–27]. AQP5 located on the basolat-
eral side can be accessed by anti-AQP5 autoantibodies
present in the tissue fluid, while AQP5 present on the apical
side of acinar cells can be accessed by anti-AQP5
autoantibodies present in saliva.
Unexpectedly, the anti-AQP5 autoantibodies were also
detected in the sera of many healthy controls at low levels.
Highly conserved AQPs are distributed throughout all the
kingdoms of life, including bacteria. It has been shown that
mouse immune serum raised against Escherichia coli
AQPZ react with human AQP4 [28]. When the bacterial
protein database was BLAST-searched using the human
AQP5 sequence as a query, AQPZ or porins from many
human-associated bacteria had a high degree of homology
with AQP5 (Supplementary Table 2). The human-
Table 1 Association between whole salivary flow and the presence of anti-AQP5 autoantibodies in SS patients
Presence of autoantibodies No. of patients Mean salivary flowa (95 % CI) P
Anti-AQP5 IgG Resting
- 28 0.097 (0.045, 0.149) 0.003b
? 63 0.050 (0.031, 0.069) 0.147c
Stimulated
- 27 0.554 (0.362, 0.747) 0.697b
? 61 0.511 (0.389, 0.633) 0.717c
Anti-AQP5 IgA Resting
- 79 0.070 (0.047, 0.093) 0.048b
? 12 0.027 (-0.011, 0.064) 0.010c
Stimulated
- 76 0.556 (0.444, 0.667) 0.057b
? 12 0.326 (0.110, 0.543) 0.089c
Anti-Ro IgG Resting
- 9 0.040 (0.002, 0.149) 0.445b
? 82 0.067 (0.044, 0.090) 0.512c
Stimulated
- 8 0.482 (0.238, 0726) 0.793b
? 80 0.529 (0.419, 0.638) 0.800c
Anti-La IgG Resting
- 42 0.066 (0.042, 0.091) 0.851b
? 49 0.062 (0.029, 0.096) 0.288c
Stimulated
– 40 0.550 (0.407, 0.692) 0.648b
? 48 0.503 (0.357, 0.649) 0.508c
a ml/min
b ANOVA
c Mann–Whitney U test
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associated bacteria containing the AQP5-homologous
proteins included infectious pathogens (Yersinia entero-
colitica, Vibrio vulnificus, Vibrio parahaemolyticus, etc.),
opportunistic pathogens (Acinetobacter baumannii, Ente-
rococcus faecalis, E. coli, Streptococcus pneumoniae, etc.),
and the members of normal flora (Enterobacter cloacae,
Neisseria subflava, Streptococcus oralis, etc.). Therefore,
there is a possibility that the autoantibodies against AQP5
were developed during an immune response against bac-
terial proteins. While IIFA showed a clear difference in the
levels of anti-AQP5 autoantibodies between the control
and SS sera, immunoprecipitation was not effective in
differentiating the control and patient samples. This dis-
crepancy could be attributed to potential differences in the
conformations and exposed epitopes of AQP5 present in
membrane versus lysates. Sequence alignment of the
selected bacterial AQPs with human AQP5 revealed that
sequences are conserved mostly at the transmembrane
alpha helixes and the water channel-forming loops B and
E (Supplementary Figure). In this regard, the anti-AQP5
autoantibodies detected in the control and SS samples
could have different effects such as inhibiting the function
of AQP5. Unfortunately, the salivary flow rates were
available only for 10 control subjects, and the effect of the
anti-AQP5 autoantibodies on salivary flow in the control
group could not be evaluated. A cell-based functional assay
to evaluate the effect of anti-AQP5 autoantibodies on water
passage through AQP5 is currently under development,
which will provide direct evidence for the role of anti-
AQP5 autoantibodies in the salivary flow. Another limita-
tion of the current study is a relatively small sample size.
Therefore, further studies using samples from larger SS
patient cohorts and diverse control subjects, including other
autoimmune diseases, are needed.
The presence of anti-Ro/SSA and/or anti-La/SSB
autoantibodies in serum is a diagnostic hallmark of SS [15].
A number of other autoantibodies such as anti-salivary
gland protein 1, anti-carbonic anhydrase 6, anti-parotid
secretory protein, anti-a-fodrin, anti-M3R, anti-nuclear,
and anti-smooth muscle antibodies have been identified in
SS [5, 6, 29]. Except for the anti-parotid secretory protein
and anti-M3R antibodies, most autoantibodies target anti-
gens that are normally present inside cells. Therefore, those
autoantibodies reflect the apoptotic destruction of gland
tissues, that is, a result of the disease process rather than the
cause of the disease [10]. The degree of salivary dysfunc-
tion in SS patients does not correlate with the degree of
glandular tissue destruction [30]. Indeed, the presence of
either anti-Ro or anti-La autoantibodies was not associated
with salivary hypofunction in the current study.
In contrast, anti-M3R autoantibodies have the potential
to interfere with the secretory process by inhibiting sig-
naling through M3R and AQP5 translocation [29, 31, 32].
The binding of autoantibodies to M3R also down-regulates
the receptors from the plasma membrane by inducing
internalization [33]. However, the functional data have not
been reconciled with the sensitivity and specificity of the
anti-M3R autoantibodies in screening trials [10]. Although
anti-M3R autoantibodies have been detected in 9–100 % of
SS patients depending on the method and antigens used
[34], a recent meta-analysis study concluded that the anti-
M3R antibody has high specificity (0.95) but relatively low
sensitivity (0.43) to diagnose SS [35]. In this aspect, the
anti-AQP5 autoantibodies identified in the current study
could complement anti-M3R autoantibodies.
In conclusion, anti-AQP5 autoantibodies were detected
in the sera of SS patients, which could be a novel bio-
marker of SS and provide new insight into the pathogenesis
of SS. In addition, association between the presence of
anti-AQP5 autoantibodies and resting salivary flow in SS
patients suggests its potential as a biomarker that reflects
disease activity.
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